회원가입 | 연락처 | 사이트맵 | English

      회사소개 | 리포트 | 커스텀 리서치 | 고객지원


로그인

카테고리

유/무선통신

전기/전자

디지털기기/미디어/방송

Information Technology

에너지

생명공학

화학/신소재

자동차

환경

일반소비재

마케팅/광고

금융

건설

교통/운송

소비자조사

방위/항공/우주

식음료

중공업

교육

기계

무역

스포츠/레저

해운/조선

패션

정부/정책

공예/귀금속

컴퍼니 프로파일

기타산업

 
현재위치 : HOME > 리포트 > 화학/신소재 > 화학
Investigation Report on China Montelukast Market, 2010-2019
발행사 China Research and Intelligence

발행일 2015-05
분량 30 pages
서비스형태 Report
판매가격

인쇄하기

Description

More than 300 million people in the world suffer from seasonal asthma to different degrees. The situation is more serious in seriously polluted countries and regions where tobacco consumption is high. Asthma and allergic rhinitis are common diseases in today’s world whose incidence has kept increasing every year due to nowadays’ severe air pollution.
Montelukast, developed by Merck, has been widely applied to the treatment of allergic rhinitis and asthma. Montelukast, a selective cysteinyl leukotriene receptor D4 antagonist, selectively combines with leukotriene in the airway and blocks the action of anaphylactic mediator so as to improve respiratory inflammation and keep airway open.
In 1998, Montelukast sodium tablets (10mg) and chewable tablets (5mg) first came into America’s market on FDA’s approval with a trade name of Singulair. In 2000 and 2002, Montelukast chewable tablets (4mg) and Montelukast granules (4mg) were approved to enter the market successively for the prevention and long-term treatment of asthma of adults and children aged at 2 or above 2.
After Singulair’s US patent expired on Aug.3, 2012, FDA has approved the generic drug applications of over 10 drug makers, among which Teva introduced tablets, chewable tablets and oral granules while Dr. Reddy’s introduced tablets and chewable tablets.
In 1999, Montelukast chewable tablets (5mg) and tablets(10mg) came into Chinese market on approval with a trade name of Singulair. Later, Montelukast chewable tablets (4mg) and granules(4mg) came into Chinese market on approval successively. The generic drugs of Montelukast tablets (10mg) and chewable tablets(5mg) made by Sichuan Otsuka was approved to enter the market in 2006 with a trade name of Bystine. Besides, there are also many other companies declaring generic drug in Chinese market.
According to CRI’s survey on some sample hospitals in China, the annual sales CAGR of Montelukast in Chinese hospitals exceeded 45% during the period of 2005-2010. With the appearance of some competitive products, the increase of Montelukast in Chinese market has slowed since 2011, but still remaining an annual growth of over 10%. Its sales CAGR still reached 25.5% during the period of 2010-2014.
It has been shown that China has more than 30 million asthma patients and 300-400 million patients suffering from allergic rhinitis. As the environmental pollution worsens in China, the number of patients will keep going up. In China, Montelukast is regarded as one of the most effective antiasthmatic drugs and therefore is estimated to enjoy huge market potential.

Readers can get at least the following information from this report:
-incidence of respiratory ailments in China
-Montelukast’s price in Chinese hospitals
-the production status of generic drugs of Montelukast in China
-major Montelukast manufacturers and their market share in China
-Market outlook of Montelukast in China

The author suggests the following groups of people purchase this report:
-manufacturers of Montelukast APIs and finished medicines
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese market of Montelukast or other medicines, please contact CRI for customized research service


회사소개 | 개인정보보호정책 | 이용약관 | 배송/결제안내 | 이용안내

서울시 강남구 논현동 210-1 삼원빌딩 | 회사명 : (주)엘앤에치
대표전화 : 02-554-0001 / 팩스 : 02-3444-5501 / 이메일 : sales@landh.co.kr
Copyright ⓒ 2008 LNH, Inc. All rights reserved.